Monkey Capital, a blockchain funding venture, recently acquired the Monkey.com domain name from a company that has owned it for over 20 years, for just $500,000. This blockchain has solely been operating from Monkey.Capital web address, and according to the venture firm’s managing partner Daniel Mark Harrison, the recent acquisition paves the way for the company to be the only one combining media, blockchain development, and crypto. He said the domain purchase price was in fact not comparable to the immeasurable value it will bring to his firm.
When asked about what plans the blockchain funding firm has for the new website, Daniel Mark Harrison added that among the new products will be a 24-hour news broadcast of programs about digital assets. The new website will also feature the Blockchain Manifesto, which is a book the managing partner
has co-authored with Joshua Hawley, the company’s Chief Operations Officer.
The American firm selling the Monkey.com to Monkey Capital will receive cash installments totaling $400,000 and the rest as COEVAL, Monkey Capital’s cryptocurrency. This new investment is a great move for Monkey Capital, a firm that is already causing ripples in the marketplace with its ICO.
This firm’s ICO is not only detailed on its website but it also enjoys Platinum accreditation on Coinschedule from the thousands of applicants who seek such listing. This, according to Coinschedule’s co-founder Alex Michaelis stems from the fact that Money Capital operates in a transparent manner that makes it stand out from the rest. Such openness makes it clear to the crypto community, who runs the firm and what it has to offer.
Monkey Capital’s rapid growth is attributed to the strong team behind it, such as the firm’s managing partner Daniel Mark Harrison who is a businessman among many other titles. His list of achievements reads long.
He is an author of books like Butterflies: The Strange Metamorphosis of Fact & Fiction in Today’s World, and a popular contributor to publications like CoinSpeaker and Marx Rand. He is also a popular face on business news programs of renowned media houses like CNN and Bloomberg, and his work has been featured on Forbes among other leading publications. He is also the CEO of Daniel Mark Harrison & Co.
Academically, Daniel Mark Harrison holds a BA, Theology from the University of Oxford, an MBA from BI Norwegian Business School and a New York University’s Master’s degree in Journalism. He is based out of Singapore.
Jim Tananbaum’s choice to name his company Foresite Capital was no coincidence. With a B.S. and a B.S.E.E. from Yale University, an M.B.A. from Harvard Business School, and an M.D. from Harvard Medical School, Jim is afforded with the intelligence and foresight to make business decisions that have time and again proven the worth of his education.
Before even graduating from medical school, Jim had already founded his first pharmaceutical company called GelTex Pharmaceuticals. Under Jim’s ownership, Geltex introduced two new drugs into the pharmaceutical market that currently make $1 billion in revenue, in spite of the less than $80 million it took GelTex to introduce the drugs. GelTex was founded in January of 1991, and Jim remained the CEO of the company until Genzyme bought it in 1992. After the purchase, Jim became a board member and remained as such until 1997. Jim also co-founded another company called Theravance, Inc in 1997. Theravance prompted a spinoff called Theravance Biopharma, Inc. He remained with Theravance until 2000.
However, Jim’s business expertise extends further into the financial arena. Jim Tananbaum is also deep-rooted in the United States’ biggest investing markets. He has investing experience from early on in his career, as Jim Tananbaum retained a partner position at Sierra Ventures from 1993 to 1997. Jim continued to found successful companies, and contributed his investing experience to his company-founding experience to co-found Prospect Venture Partners II and Prospect Venture Partners III in 2001. Jim stayed at Prospect Venture Partners as the Managing Director until 2010, when he left to yet again found a substantially successful company. Foresite Capital Management, a healthcare equity growth firm, is where Jim has worked since its founding. Foresite Capital is a San Francisco-based company, but also has an office in New York. Again using his prior education and experience to his advantage, many of the investments Jim has led at Foresite Capital have been in successful pharmaceutical companies. Amira Pharmaceuticals and Jazz Pharmaceuticals are among the companies in which Jim has invested. Jim has recently been named to the Forbes Midas List of the US Top 100 Investors, on which he is currently ranked #52.
See more: https://www.linkedin.com/in/jim-tananbaum-a7562a7/